Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Infertility Treatment Market
The infertility treatment market addresses a persistent and growing global need driven by rising infertility rates, delayed parenthood, and increasing societal acceptance of assisted reproductive technologies (ART). The market encompasses a broad range of procedures, products, and services designed to support individuals and couples in achieving conception, including in-vitro fertilization (IVF), gamete donation, surrogacy, and advanced diagnostic and therapeutic tools. Technological advancements, regulatory support, and expanding access to fertility services are key factors contributing to market expansion.
The market is segmented by procedure, product, patient type, end user, and region, reflecting its diverse and evolving landscape.
Market size
Growth trajectory through 2035
Infertility Treatment Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 AI-driven diagnostics
- The integration of artificial intelligence in fertility treatments has improved embryo selection, diagnostic accuracy, and treatment personalization.
-
Development 02 Automation in laboratories
- Automated systems for embryo culture and genetic testing have enhanced efficiency and reduced human error.
-
Development 03 Telemedicine expansion
- Digital health platforms are making fertility consultations and follow-ups more accessible, particularly in underserved regions.
-
Development 04 Government initiatives
- Policies aimed at lowering the cost of IVF medications and expanding insurance coverage for fertility treatments have improved access to care.
Emerging opportunities added
- AI and automation in fertility treatments The integration of AI-driven diagnostics, predictive analytics, and automation in laboratory processes is improving treatment success rates and reducing costs, creating opportunities for innovation and market differentiation.
- Expansion of telemedicine and digital health platforms Teleconsultations and patient management systems are making fertility services more accessible, particularly in underserved regions, and reducing the burden on physical clinics.
- Growth in fertility preservation Increasing acceptance of egg freezing and sperm banking, driven by delayed parenthood and career priorities, is expanding the market for fertility preservation services.
- Regional market expansion Emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa are experiencing rapid growth due to rising infertility rates, improving healthcare infrastructure, and increasing disposable income.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $4.09 Bn
- CAGR
- 7.80%
- Expansion
- 2.1×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- chart
- Top-5 concentration
- Low · ~35%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory hurdles
- Named players
- 22 profiled
- Growth peak
- 2027–2031
Latest development
AI-driven diagnostics: The integration of artificial intelligence in fertility treatments has improved embryo selection, diagnostic accuracy, and treatment personalization
+6 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Infertility Treatment Market today ($4.09 Bn base), and how fast will it grow at 7.8% CAGR through 2035?
- How do NORTH AMERICA compare on market share, growth rate, and regulatory posture?
- Where do Allergan Aesthetics (AbbVie), Galderma S.A, Merz Aesthetics and 19 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising infertility prevalence) and top restraints (led by Regulatory hurdles), with quantified CAGR impact?
- What regulatory shifts and 7 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising infertility prevalence Infertility affects approximately 17.5% of people globally, with male and female factors contributing significantly to the burden. Male infertility accounts for 20–30% of cases, while female infertility contributes to 20–35%, and combined factors account for 25–40%.
- Delayed parenthood Societal trends toward delayed childbearing, particularly in developed economies, have increased the urgency for fertility interventions as age-related fertility decline becomes more pronounced.
- Technological advancements Innovations in reproductive medicine, such as genetic testing, advanced semen analysis, AI-driven diagnostics, and improved IVF techniques, are enhancing treatment success rates and accessibility.
- Increasing acceptance of ART Growing societal acceptance of assisted reproductive technologies, including IVF, surrogacy, and fertility preservation, has expanded the patient pool and normalized seeking treatment.
- Government initiatives and funding Policies promoting family planning, financial support for fertility treatments, and expanded insurance coverage are encouraging more individuals and couples to pursue fertility services.
- Expansion of fertility clinics and infrastructure The proliferation of specialized fertility centers, particularly in regions like Asia-Pacific and North America, is improving access to care and driving market growth.
Restraints
Holding it back
- Regulatory hurdles Approval timelines for fertility treatments and technologies can extend by 6–12 months post-2025, delaying market entry for new products and services.
- High treatment costs The financial burden of infertility treatments, including IVF and related procedures, remains a significant barrier for many patients, despite efforts to lower costs through government initiatives and employer-sponsored benefits.
- Limited awareness in developing regions While awareness of infertility and its treatments is growing, many developing regions still lack sufficient education and access to fertility services, constraining market expansion.
- Ethical and legal complexities Surrogacy and gamete donation are subject to varying legal frameworks across regions, creating operational challenges and limiting market uniformity.
- Supply chain disruptions Component shortages for fertility-related instruments and technologies, particularly in the post-pandemic period, have impacted production and availability.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising infertility prevalence | +3.5% | Global | 2025–2035 |
| Delayed parenthood | +2.2% | Global | 2025–2035 |
| Technological advancements | +1.7% | Global | 2025–2035 |
| Increasing acceptance of ART | +1.2% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory hurdles | −1.4% | Global | 2025–2029 |
| High treatment costs | −0.9% | Global | 2025–2029 |
| Limited awareness in developing regions | −0.7% | Global | 2025–2029 |
The infertility treatment market is segmented by procedure, product, patient type, end user, and region, reflecting its diverse and evolving landscape.
Revenue share by type · 2025 base year
% OF $4.09 BN INFERTILITY TREATMENT MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $4.09 Bn Infertility Treatment Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By end-user industry
-
chart
-
template="vbar_gradient" data
-
palette="muted_green">
-
color="#065f46"/>
-
color="#6ee7b7"/>
-
size="15" fill="#0f172a" text
-
anchor="middle" font
-
weight="bold">Regional Coverage
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $4.09 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~43.8% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low concentration. 22 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The infertility treatment market is characterized by a mix of established pharmaceutical companies, biotech firms, and specialized fertility clinics. Competition is driven by technological innovation, regulatory approvals, and the ability to provide comprehensive and accessible fertility services.
Concentration snapshot
Top 5 players control 35.0% of the market
Aggregate 2025 share of the top 5 named players (real market share data). Individual company shares in the full report.
Competitive tiers
Players are bucketed by base-year market share: Leaders ≥ 7%, Challengers 3–7%, Emerging < 3%. Full tier rationale + revenue estimates in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Johnson & Johnson · Merck · Novartis
Tier 2 · Challengers
4companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Roche · AbbVie · Eli Lilly · AstraZeneca
Tier 3 · Emerging
15companies
Niche or early-stage, differentiated technology or early-mover positioning.
Allergan Aesthetics (AbbVie) · Galderma S.A · Merz Aesthetics · Bausch Health Companies · Hologic Inc
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Allergan Aesthetics (AbbVie)
Rank 01Share est. ~13%Revenue $■■■MHQ ■■■ -
Galderma S.A
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Merz Aesthetics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Bausch Health Companies
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Lumenis Ltd
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Cynosure (Hologic)
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Cutera Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 14 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of infertility treatment market?
Infertility treatment market is expected to grow at 8.2% CAGR from 2023 to 2030. it is expected to reach above USD 3.04 billion by 2030 -
• What is the size of the North America in infertility treatment industry?
North America held more than 38% of infertility treatment market revenue share in 2021 and will witness expansion in the forecast period. -
• What are some of the market's driving forces?
The main factors influencing the global market for infertility treatments are the falling fertility rate, the rise in fertility clinics around the world, technological advancements, the acceleration of public-private investments, resources, grants, and the rising use of surrogacy by same-sex couples and single parents. -
• Which are the top companies to hold the market share in infertility treatment market?
Surelife Pte Ltd., Biogenics Inc., Cook Group Incorporated, Esco Micro Pte. Ltd., Genea Limited, CCRM, Ferring Pharmaceutical, Merck & Co, Monash IVF Group, The Cooper Company, Thermo Fisher, United Healthcare Group. -
• What is the leading segment of infertility treatment market?
The use of ART, IVF, gamete donation, surrogacy, and other procedures fosters market expansion by improving access to effective treatments for infertility issues worldwide.
The Infertility Treatment Market is projected to reach $8.67 Bn by 2035, up from $4.09 Bn in 2025 — a 7.80% CAGR equating to roughly 2.1× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.